Myotonic dystrophy (MD) is a group of inherited diseases characterized by progressive muscle weakness and myotonia, i.e. impaired muscle relaxation after contraction. The clinical picture of the disease is diverse and may include not only muscle symptoms, but also extranergic manifestations, such as cataracts, cardiovascular disorders, endocrine dysfunction and psychoemotional disorders. Currently, two main forms of myotonic dystrophy are known: type I (Duchenne disease or myotonic dystrophy type 1, caused by a mutation in the DMPK gene on chromosome 19) and type II (myotonic dystrophy type 2, associated with a mutation in the CNBP gene on chromosome 3). These diseases belong to the group of myopathies and require a thorough approach to diagnosis and treatment, taking into account a multidisciplinary approach.
History of the disease and interesting historical facts
The first description of myotonic dystrophy was made in 1905 by the Austrian neurologist Arnold Sigle, who identified this disease as a separate nosological entity. In the following decades, studies were conducted confirming the hereditary nature of the disease. In 1992, the mutation causing myotonic dystrophy type 1 was identified, which became an important milestone in molecular genetics. Interestingly, this type of myopathy is often associated with a family and can be inherited for several generations. The molecular structure of the DMPK gene, which the researchers studied, turned out to be the key to understanding the pathogenesis of this disease and opened up new horizons in the treatment of myotonic dystrophy.
Epidemiology
According to epidemiological studies, myotonic dystrophy type 1 occurs with a frequency of about 1 in 8,000-12,000 newborns. The frequency of myotonic dystrophy type 2 is much lower, estimated at one in 100,000 people. The prevalence of the disease may vary depending on ethnicity and region of residence. It is important to note that underestimation of cases of MD may occur due to the gradual onset of the disease and the variety of clinical manifestations, which makes diagnosis difficult.
Genetic predisposition to this disease
Myotonic dystrophy type 1 is caused by an expansion of a trinucleotide repeat (CTG) in the 3'-noncoding region of the DMPK (dystrophia myotonica protein kinase) gene located on chromosome 19. While myotonic dystrophy type 2 is caused by a mutation in the CNBP (cchushi-nager protein) gene. Genetic predisposition to this disease is due to autosomal dominant inheritance, which means that only one copy of the mutated gene is necessary for the disease to manifest. The emergence of new mutations is also possible, which is supported by the observation of random walking repeats in patients with myotonic dystrophy.
Risk factors for the development of this disease
Major risk factors for myotonic dystrophy include:
- Vertical heredity in families with a history of the disease.
- Recurrent mutations in first- and second-degree relatives may also be a risk factor.
- Exposure to certain environmental factors may contribute to the progression of symptoms, such as strenuous exercise.
- Certain chemicals may worsen the condition, such as medically used steroids.
Although myotonic dystrophy is caused by genetic changes, the environment may play a role in the severity of symptoms and the course of the disease.
Diagnosis of this disease
Diagnosis of myotonic dystrophy includes both clinical and laboratory research methods, and in some cases radiological diagnostics. The main symptoms of the disease may include:
- Myotonia is a slow relaxation of muscles after contraction.
- Progressive muscle weakness, usually symmetrical.
- Increase in muscle mass (eg Vizzer Yacht) at the expense of adipose tissue.
- Heart rhythm disturbances and development of cataracts.
Laboratory tests may include electromyography (EMG), which detects myotonic discharges, and blood tests to detect mutations associated with the disease. Radiologic studies, such as MRI, may help visualize changes in the muscles. Differential diagnosis requires exclusion of other myopathies and neurologic conditions with a similar clinical picture.
Treatment
Treatment of myotonic dystrophy currently remains symptomatic and includes both pharmacological and non-surgical therapy. The main approaches to treatment are:
- Pharmacological therapy is aimed at relieving myotonia and may include dantrolene and quinidine.
- Physical therapy is key to maintaining muscle function and improving muscle condition.
- In some cases, surgery may be needed to correct disease-related curvatures or other musculoskeletal disorders.
- Other treatments may include the use of assistive devices such as orthoses or breathing devices.
It is important to take into account a multidisciplinary approach to treatment: the involvement of specialists of various profiles for the complete management of the disease.
List of medications used to treat this disease
Medications used for myotonic dystrophy may include:
- Dantrolene is a muscle relaxant used to reduce myotonia.
- Quinidine is an antiarrhythmic drug that can help with heart problems.
- Carbamazepine - used to control myotonia.
- Tizanidine is a muscle relaxant used to relieve spasms.
Additional measures include vitamin D and calcium to support bone tissue.
Disease monitoring
Monitoring of myotonic dystrophy includes regular assessment of the degree of functional insufficiency, control of the cardiovascular system, and monitoring of the state of psychoemotional health. The control stages may be as follows:
- Regular checks of vital signs, including measurements of lung function and heart function.
- Systematic assessments of muscle strength and functionality.
- The prognosis for the disease typically ranges from moderate to severe, with a significantly increased risk of complications such as heart failure.
Complications of this disease may include rhythm disturbances and blood sugar development, the treatment of which requires an individual approach.
Age-related features of the disease
Myotonic dystrophy has its own characteristics depending on the patient's age. In childhood, the disease may manifest itself more mildly, with less pronounced symptoms. However, with age, progression and aggravation of the clinical picture is observed. In adults, myotonia, muscle weakness and extramuscular manifestations are more pronounced. In elderly patients, rapid development of cardiovascular diseases may be observed, which requires special attention.
Questions and Answers
- What is the main cause of myotonic dystrophy? The underlying cause of myotonic dystrophy is due to mutations in certain genes, such as DMPK and CNBP, which lead to abnormal muscle fiber function.
- What are the first symptoms of myotonic dystrophy? Early symptoms may include myotonia, muscle weakness and fatigue, as well as extramuscular manifestations such as heart problems and cataracts.
- What is the treatment approach for myotonic dystrophy? Treatment involves a symptomatic approach, including pharmacological therapy, physical rehabilitation and regular monitoring by health professionals.
- How often are screenings recommended for myotonic dystrophy? Examinations are recommended on a regular basis, at least once a year, to monitor the condition and adjust treatment, especially in the presence of extramuscular complications.
- Can myotonic dystrophy appear later in life? Yes, it can manifest itself later in life, but milder forms of the disease often go unnoticed and can progress with age.
